Vanda Pharmaceuticals stock, Pharmaceuticals

Vanda Pharmaceuticals stock slips as 2025 loss widens

Published on 09/18/2026 at 19:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vanda Pharmaceuticals stock fell 0.39 percent to USD 5.09 on September 18, 2026. Reuters shows 2025 revenue at USD 216.1 million and net loss at USD 220.5 million.

Vanda Pharmaceuticals stock, Pharmaceuticals, Nasdaq, Illustration mit AI erstellt.

Vanda Pharmaceuticals stock (ISIN US9216591084) traded at USD 5.09 on September 18, 2026, down 0.39 percent, with Reuters showing 2025 revenue of USD 216.1 million and a net loss of USD 220.5 million.

Revenue and loss

According to Reuters, Vanda Pharmaceuticals Inc. reported revenue of USD 216.105 million in 2025, up from USD 198.772 million in 2024. Net income was minus USD 220.474 million in 2025 after a loss of USD 18.9 million in 2024.

What the market sees

The same Reuters market page put the stock at USD 5.09 on September 18, 2026, with a change of minus 0.02 dollar, or minus 0.39 percent, and showed 72,161 shares traded. That leaves the shares far below the scale implied by the 2025 revenue base.

Stock near USD 5

Vanda Pharmaceuticals stock ended the latest snapshot at USD 5.09 on September 18, 2026. The move was small, but the 2025 figures point to a business that is still carrying a large loss.